Business
Novartis Pelacarsen Miss Shrinks Multibillion-Dollar Lp(a) Market
Pelacarsen cut Lp(a) but failed to reduce heart attacks or strokes in a late-stage trial, denting Novartis and raising the stakes for Amgen and Eli
Pelacarsen cut Lp(a) but failed to reduce heart attacks or strokes in a late-stage trial, denting Novartis and raising the stakes for Amgen and Eli